Genmab Presents Promising Epcoritamab Data In Elderly DLBCL Patients
(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed diffuse large B-cell lymphoma (DLBCL) who are not el…
(RTTNews) - Genmab A/S (GMAB) reported positive findings from two clinical studies evaluating epcoritamab in elderly patients with newly diagnosed dif
Read Full Story at Nasdaq News →Why This Matters
The data from Genmab’s epcoritamab trials in elderly DLBCL patients could redefine frontline treatment standards by demonstrating that off-the-shelf bispecific antibodies can match or exceed the efficacy of traditional chemo-immunotherapy regimens—without the attendant toxicity. For a rapidly aging global population, where DLBCL incidence rises sharply with age, this represents a paradigm shift toward more accessible and tolerable oncology care.
Background Context
DLBCL, the most common lymphoma subtype, has historically relied on R-CHOP, a chemotherapy backbone unchanged for decades despite its harsh side effects in frail elderly patients. While CD19-directed CAR-T therapies have revolutionized relapsed/refractory settings, their complex logistics and cost have limited availability for newly diagnosed cases. Epcoritamab, a subcutaneously administered bispecific antibody, bridges this gap by offering outpatient administration and lower systemic toxicity.
What Happens Next
Regulatory submissions for epcoritamab in frontline DLBCL are likely imminent, with data from these elderly cohorts potentially accelerating approval timelines. Clinicians will soon face critical decisions on combining epcoritamab with other agents like lenalidomide or polatuzumab vedotin, while payers will grapple with pricing pressures in an increasingly competitive bispecific landscape dominated by AbbVie’s epcoritamab and Roche’s glofitamab.
Bigger Picture
This development underscores the accelerating shift toward "chemotherapy-free" oncology, where antibody-based therapies and cell-based treatments are narrowing the gap between innovation and accessibility. The success of bispecifics in elderly DLBCL patients could also spur similar trials in other aggressive hematologic malignancies, further cementing their role as the cornerstone of modern lymphoma treatment.
